Breast cancer highly deteriorates the lifespan and the life quality of women around the world. The Triple Negative Breast Cancer (TNBC) represents only 15% of all breast cancer subtypes. Nevertheless, it is characterized by a high death rate. TNBC is highly aggressive and exhibits poor prognosis, being insensitive to conventional targeted anti-breast cancer treatments. It is therefore crucial to develop new therapies against TNBC. As in many other cancers, the signaling of the Wingless/Int (Wnt) family of growth factors is overly active in TNBC, being one of the causes of carcinogenesis. During my master a was a member of research laboratories located in the Department of Cell Physiology and Metabolism (PHYM) at the University of Geneva. One of them has hitherto identified a pool of compounds that target the Wnt pathway and has additionally shown very promising activities against TNBC cells in vitro and in vivo. To assess their toxicity, we decided to proceed by using high throughput screen assays on the Nematode C. elegans. The validation of the new protocol would allow to test the toxicity of a high number of molecules to employ in the preclinical development of the drug candidates against TNBC. My project is part of our laboratory pipeline of anti-Wnt anticancer drug discovery. Over the next few years, the compounds eventually emerging from this pipeline might become specific drugs, ultimately saving human lives from TNBC.